Emergent Biosolutions Inc [NYSE: EBS] gained 34.18% on the last trading session, reaching $6.36 price per share at the time.
If compared to the average trading volume of 1.24M shares, EBS reached a trading volume of 4716552 in the most recent trading day, which is why market watchdogs consider the stock to be active.
Here is what top equities market gurus are saying about Emergent Biosolutions Inc [EBS]:
Based on careful and fact-backed analyses by Wall Street experts, the current consensus on the target price for EBS shares is $13.50 per share. Analysis on target price and performance of stocks is usually carefully studied by market experts, and the current Wall Street consensus on EBS stock is a recommendation set at 2.33. This rating represents a strong Buy recommendation, on the scale from 1 to 5, where 5 would mean strong sell, 4 represents Sell, 3 is Hold, and 2 indicates Buy.
H.C. Wainwright have made an estimate for Emergent Biosolutions Inc shares, keeping their opinion on the stock as Buy, with their previous recommendation back on December 30, 2024. While these analysts kept the previous recommendation, Rodman & Renshaw raised their target price to Buy. The new note on the price target was released on August 22, 2024, representing the official price target for Emergent Biosolutions Inc stock. Previously, the target price had yet another raise to $5, while The Benchmark Company analysts kept a Buy rating on EBS stock.
The Average True Range (ATR) for Emergent Biosolutions Inc is set at 0.48, with the Price to Sales ratio for EBS stock in the period of the last 12 months amounting to 0.36. The Price to Book ratio for the last quarter was 0.63, with the Price to Cash per share for the same quarter was set at 2.81. Price to Free Cash Flow for EBS in the course of the last twelve months was 3.66 with Quick ratio for the last quarter at 3.51.
Trading performance analysis for EBS stock
Emergent Biosolutions Inc [EBS] gain into the green zone at the end of the last week, gaining into a positive trend and gaining by 29.27. With this latest performance, EBS shares gained by 48.60% in over the last four-week period, additionally sinking by -27.48% over the last 6 months – not to mention a rise of 59.80% in the past year of trading.
Overbought and oversold stocks can be easily traced with the Relative Strength Index (RSI), where an RSI result of over 70 would be overbought, and any rate below 30 would indicate oversold conditions. An RSI rate of 50 would represent a neutral market momentum. The current RSI for EBS stock in for the last two-week period is set at 65.72, with the RSI for the last a single of trading hit 73.09, and the three-weeks RSI is set at 59.08 for Emergent Biosolutions Inc [EBS]. The present Moving Average for the last 50 days of trading for this stock 5.31, while it was recorded at 5.20 for the last single week of trading, and 8.26 for the last 200 days.
Emergent Biosolutions Inc [EBS]: A deeper dive into fundamental analysis
Emergent Biosolutions Inc’s liquidity data is similarly interesting compelling, with a Quick Ratio of 3.51 and a Current Ratio set at 6.32.
An analysis of Institutional ownership at Emergent Biosolutions Inc [EBS]
The top three institutional holders of EBS stocks are: BLACKROCK INC. with ownership of 3.84 million shares, which is approximately 7.2992%. VANGUARD GROUP INC, holding 3.67 million shares of the stock with an approximate value of $$25.0 million in EBS stocks shares; and VANGUARD GROUP INC, currently with $$21.59 million in EBS stock with ownership which is approximately 6.0195%.
